BCRX vs RNA
BCRX: BioCryst Pharmaceuticals is a biotech company focused on commercializing and developing innovative therapies for hereditary angioedema and other rare diseases using structure-guided drug design. RNA: Atrium is an early-stage biotech pioneering antibody-conjugated RNA therapeutics to treat rare genetic cardiomyopathies by silencing disease-driving genes in the heart.
Side-by-side fundamentals
| Metric | BCRX | RNA | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $9.51 | $12.17 | |
| Market cap as of 2026-07-23 | $2.4B | $210M | |
| P/E as of 2026-07-23 | 9.20 | n/a | |
| PEG as of 2026-07-23 | -0.01 | n/a | |
| Net margin as of 2026-07-23 | -51.7% | -172.9% | BCRX higher |
| Gross margin as of 2026-07-23 | +97.8% | n/a | |
| Operating margin as of 2026-07-23 | -45.1% | -174.9% | BCRX higher |
| ROE as of 2026-07-23 | -328.8% | -40.3% | RNA higher |
| ROA as of 2026-07-23 | -97.3% | -592.6% | BCRX higher |
| Debt / equity as of 2026-07-23 | 2.26 | 0.00 | RNA lower |
| Revenue growth (YoY) as of 2026-07-23 | +75.9% | +22.0% | BCRX higher |
| Revenue CAGR (3y) SEC XBRL | +22.8% | n/a | |
| Beta as of 2026-07-23 | 0.57 | 0.98 | |
| 1-year return as of 2026-07-22 close | +9.9% | -63.9% | BCRX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.